Shares of Gilead Sciences ( GILD) continued to rise Thursday after the company announced that second-quarter profits rose from a year ago, driven by strong sales of its HIV treatment, Viread.

After the end of trading on Thursday, Gilead announced second-quarter net income of $111.5 million, or 49 cents a share, up 11% from the $100.4 million, or 46 cents a share, it had a year ago.

Analysts expected the company to earn 35 cents a share in the second quarter. Shares closed up $1.25, or 2.2%, to $59.50 and continued to rise, adding another $2.39, or 4%, to $61.89 after hours.

Excluding a $50.1 million provision for income taxes, the company said it earned $161.5 million, up 53% from last year's $105.6 million.

Revenue came in at $319.7 million, up 34% from the year-ago $238.9 million. Gilead posted product sales of $299.3 million, up 30% year-over-year, driven by record sales of its HIV-fighter Viread, which came in at $197 million, up 18% from last year. The company said currency effects boosted sales of Viread by $5.8 million.

Sales of its other drugs continued to grow as well. AmBisome sales were $55 million, up 7%, while sales of Hepsera came in at $28 million, more than double year-ago levels.

Expenses rose 20.6% in the quarter, coming in at $119.4 million, up from $99 million last year.

If you liked this article you might like

Check the Math on Air Fares

Check the Math on Air Fares

US Airways Circles as Pilots Bicker

US Airways Circles as Pilots Bicker

Departure of Delta's Song Unit Boss Stirs Questions

Departure of Delta's Song Unit Boss Stirs Questions

Boeing Boosts Jet Deliveries

Boeing Boosts Jet Deliveries

CEO Gilmartin Will Survive Recall

CEO Gilmartin Will Survive Recall